康健集团(03886.HK)向市民提供受「港康码」认可的深喉唾液核酸检测
康健集团(03886.HK)公布,配合香港政府即将推出「港版健康码」,容许通过2019冠状病毒病核酸检测的特定人士,豁免隔离14日检疫往来粤港澳三地的安排,特以950港元向市民提供受「港康码」认可的深喉唾液核酸检测。
950港元的费用包括一次医生评估、深喉唾液核酸检测及检测报告。市民可於提交检测样本的第二个工作天获取检测报告。
康健集团为了支持政府「港康码」计划,与「港康码」认可检测机构—香港分子病理检验中心合作,於7月2日起在旗下40间普通科诊所,联同Dr. Vio & Partners韦予力医生医务所3间综合医务中心、基督教灵实协会诊所、(柏)峰医务中心及御康医务中心共同推出符合「港康码」要求的核酸检测,又将价格推向较易负担的水平,希望市民可以在疫情受控下,尽快恢复正常生活。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.